NCT03945773 2026-03-13
CaboPoint
Ipsen
Phase 2 Completed
Clinical Trials
19 trialsNCT03798626 2026-01-27
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Novartis
Phase 1 Completed
NCT03685448 2025-08-08
UNICAB
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Completed
NCT03967522 2025-08-08
CABRAMET
Centre Leon Berard
Phase 2 Completed
NCT04804813 2025-04-11
Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma
Takeda
Completed
NCT04338269 2025-04-04
CONTACT-03
Hoffmann-La Roche
Phase 3 Completed
NCT03149822 2025-03-13
Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma
University of Colorado, Denver
Phase 1/2 Completed
NCT02761057 2025-01-13
Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
National Cancer Institute (NCI)
Phase 2 Completed
NCT03200587 2024-07-03
Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)
University of Utah
Phase 1 Completed
NCT04540705 2024-02-28
PIVOT IO 011
Bristol-Myers Squibb
Phase 1 Completed
NCT04134390 2024-01-09
CABOMAYOR
Spanish Oncology Genito-Urinary Group
Phase 2 Completed
NCT03428217 2023-03-20
CANTATA
Calithera Biosciences, Inc
Phase 2 Completed
NCT04510688 2022-10-26
SRWEC
Spanish Oncology Genito-Urinary Group
Completed
NCT02071862 2022-07-20
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Calithera Biosciences, Inc
Phase 1 Completed
NCT03354884 2021-05-10
BONSAI
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT01865747 2021-04-27
METEOR
Exelixis
Phase 3 Completed
NCT03463681 2021-04-26
BREAKPOINT
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT01835158 2021-02-11
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT04637204 2021-02-01
Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in England
Ipsen
Completed